Intravitreal bevacizumab for myopic choroidal neovascularization.
作者信息
Rensch Florian, Spandau Ulrich H M, Schlichtenbrede Frank, von Baltz Stefan, Libondi Teodosio, Jonas Jost B, Vossmerbaeumer Urs
机构信息
Department of Ophthalmology, Medical Faculty Mannheim of the Ruprecht-Karls-University Heidelberg, Mannheim, Germany.
出版信息
Ophthalmic Surg Lasers Imaging. 2008 May-Jun;39(3):182-5. doi: 10.3928/15428877-20080501-14.
BACKGROUND AND OBJECTIVE
To evaluate the effect of intravitreal bevacizumab on visual acuity in patients with myopic choroidal neovascularization.
PATIENTS AND METHODS
The retrospective case series study included 13 patients with myopic choroidal neovascularization who received three intravitreal injections of 1.5 mg of bevacizumab.
RESULTS
At 1, 3, and 6 months after the first injection, mean visual acuity improved significantly from 0.63 +/- 0.41 logarithm of the minimum angle of resolution units (LogMAR) to 0.39 +/- 0.22 (P< .001), 0.47 +/- 0.49 (P= .002), and 0.52 +/- 0.49 LogMAR (P = 0.009), respectively. The increase in visual acuity was correlated with a significant decrease in central retinal thickness (P = .003) as measured by optical coherence tomography. Mean intraocular pressure did not change significantly (P> .05) during follow-up.
CONCLUSION
Intravitreal injections of bevacizumab may be a therapeutic option for exudative myopic macular degeneration.
Zotero 插件